Morphogenesis, Inc. Signs Agreement With Novartis Corporation to Further the Development of Cancer Immunotherapy for Companion Animals

TAMPA, Fla.--(BUSINESS WIRE)--Morphogenesis Inc. recently announced that one of its platform technologies, an investigational immunotherapy treatment for cancers, will be developed by Morphogenesis and Novartis Animal Health under an exclusive worldwide co-development and commercialization agreement entered into in November 2009. Through this agreement, Morphogenesis and Novartis will work closely together to advance the new platform technology to the companion animal market.

Back to news